Duloxetine
Product Images NDC 60687-734

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60687-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20 mg Duloxetine Delayed-release Capsule Blister (20 mg Blister)

A sheet containing multiple identical labels for Duloxetine 20 mg delayed-release capsules USP. Each label includes the product name, strength, dosage form, placeholder text for lot number and expiry date, a barcode, and the labeler name American Health Packaging. The labels are arranged in a grid pattern.*

FDA Label Image

20 mg Duloxetine Delayed-release Capsules Carton (20 mg Carton)

Label for Duloxetine delayed-release capsules USP, 20 mg strength, distributed by American Health Packaging. The label indicates a package size of 30 capsules (3 x 10). The label also includes instructions for pharmacists, dosage contents, storage conditions, and a warning to keep the drug out of reach of children.*

FDA Label Image

30 mg Duloxetine Delayed-release Capsule Blister (30 mg Blister)

Labels for Duloxetine Delayed-Release Capsules USP 30 mg by American Health Packaging. Each label includes the drug name, strength, delayed-release capsule dosage form, lot number placeholder, expiration date placeholder, and a barcode. The design is repeated multiple times on the sheet for individual labeling use.*

FDA Label Image

30 mg Duloxetine Delayed-release Capsules Carton (30 mg Carton)

Label for Duloxetine Delayed-Release Capsules USP, 30 mg strength, containing 100 capsules (10 x 10). The label includes NDC 60687-734-01, indicates Rx Only, and specifies storage instructions and safety warnings. Distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

60 mg Duloxetine Delayed-release Capsule Blister (60 mg Blister)

Sheet of labels for Duloxetine Delayed-Release Capsule USP 60 mg by American Health Packaging, Columbus, OH. Each label displays the product name, strength, dosage form, lot number placeholder, expiration date placeholder, and barcode. The design is repeated multiple times on the sheet.*

FDA Label Image

60 mg Duloxetine Delayed-release Capsules Carton (60 mg Carton)

Label for Duloxetine Delayed-Release Capsules USP 60 mg by American Health Packaging. The label shows the strength as 60 mg and package size as 100 capsules (10 x 10). Includes barcode, NDC 60687-745-01, and usage instructions for pharmacists and storage conditions. Distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

Ahp72321

Duloxetine capsule, yellow in color, printed with 'X' on one half and '01' on the other half. No additional strength, dosage form, or labeler details are visible on the capsule itself.*

FDA Label Image

Ahp74501

Duloxetine capsule imprints 'X 03' showing a blue and yellow two-tone, oval-shaped capsule. The capsule has a dark imprint on the blue half and appears smooth and glossy. The image includes a millimeter scale for size reference, labeled under American Health Packaging.*

FDA Label Image

Figure 1: Cumulative Proportion Of Adult Patients With Mdd Relapse (study Mdd-5) (Figure1)

A survival curve chart comparing the proportion of patients with relapse over time in days from randomization for Duloxetine versus Placebo treatment groups. The x-axis represents time in days, and the y-axis shows the proportion of patients with relapse, with Duloxetine represented by a solid line and Placebo by a dashed line.*

FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Figure10)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline (BOCF) between Placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis represents percentage of patients improved. Duloxetine shows a higher percentage of patient improvement across most pain improvement levels compared to Placebo.*

FDA Label Image

Figure 2: Cumulative Proportion Of Adult Patients With Gad Relapse (study Gad-4) (Figure2)

A line graph showing the proportion of patients with relapse over time (days) from randomization. Two treatment groups are compared: placebo (dashed line) and Duloxetine (solid line). The x-axis shows time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0.*

FDA Label Image

Figure 3: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-1) (Figure3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine at 60 mg BID, 60 mg QD, 20 mg QD, and placebo, with lines representing patient improvement rates for each group.*

FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Figure4)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Two Duloxetine dosing regimens are depicted with distinct lines, compared against placebo.*

FDA Label Image

Figure 5: Percentage Of Adult Fibromyalgia Patients Achieving Various Levels Of Pain Relief At Study Endpoint As Measured By 24-hour Average Pain Severity (study Fm-1) (Figure5)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows data for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating pain improvement outcomes over a range of percentages.*

FDA Label Image

Figure 6: Percentage Of Adult Fibromyalgia Patients Achieving Various Levels Of Pain Relief At Study Endpoint As Measured By 24-hour Average Pain Severity (study Fm-2) (Figure6)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, and 20 mg once daily, compared to placebo. The graph plots percent improvement on the x-axis and percent of patients improved on the y-axis, displaying the efficacy of various Duloxetine doses relative to placebo.*

FDA Label Image

Figure 8: Percentage Of Adult Patients With Clbp Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Clbp-1) (Figure8)

A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo across various percent improvement thresholds in pain from baseline (BOCF). The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Two lines chart patient improvement rates at different pain reduction levels.*

FDA Label Image

Figure 9: Percentage Of Adult Patients With Clbp Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Clbp-3) (Figure9)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline (BOCF). The graph shows two lines: Duloxetine 60 mg once daily and Placebo, with Duloxetine generally showing higher patient improvement percentages across increasing pain improvement percentages.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of duloxetine showing its molecular arrangement, including a naphthalene ring, thiophene ring, and an amine group with hydrochloride (HCl).*

FDA Label Image

F41f22b4 468b 72e5 E053 2a95a90afb5e

Duloxetine capsules manufactured by American Health Packaging, blue and white in color. One side of the capsule is blue with a black imprint of the letter 'X', and the white side is imprinted with the number '02' in black.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.